Good morning. If you live in D.C. and took any tank pics last night, make sure you tweet them.
Today's word count is 840 words, ~3 minutes.
Medicare for All would result in payment cuts for most providers, and a recent analysis in JAMA by Harvard's Zirui Song takes a look at just how steep those cuts would be.
Details: This is a feature, not a bug, of Medicare for All. Part of the point is to spend less on health care — through steep cuts in how much many doctors and hospitals get paid.
Yes, but: The figures above represent the change in how much doctors would get paid for patients who currently have private insurance — not the total pay change across all of their patients.
What they're saying: "The assumption that physicians and hospitals would not react as their commercial prices are reduced substantially to Medicare levels is likely unrealistic," Song writes.
The bottom line: Setting rates above Medicare levels would be less disruptive, as would phasing in the changes over time, Song argues.
Why it matters: Experts cite online misinformation on Facebook and other platforms as creating real-world health problems.
Between the lines: YouTube has also been taking some action against bad health care content by cutting off advertising for bogus cancer-treatment channels, according to the Wall Street Journal.
The big picture: Facebook has mostly figured out how to weed out scam posts that have been uploaded by bots, but it's had a much harder time filtering out content uploaded by humans that doesn't explicitly violate its rules.
Go deeper: Anti-vaccination content haunts Big Tech
It's too soon to throw in the towel on biosimilars, especially because there's evidence that they're lowering the net costs of biologics, Alex Brill and Benedic Ippolito of the American Enterprise Institute argue in a Health Affairs blog.
What they're saying: The number of biosimilars in development is increasing, and 2 biologics facing biosimilar competition — Neupogen and Remicade — have begun offering bigger discounts to stay competitive, even though their list prices haven't come down.
The bottom line: "Although prices likely will not reach close to marginal costs...this does not imply that biologics, writ large, are natural monopolies in any traditional sense of the concept," Brill and Ippolito write.
Health care researchers have been warring recently over whether "accountable care organizations" have been successful. Nursing homes have a particularly dim view of that care model, Axios' Bob Herman writes.
The intrigue: Skilled Nursing News spoke with an anonymous nursing-home operator who argued hospitals and doctors have cut referrals to nursing homes to save money for their ACOs, and instead have routed patients to their own home care companies.
The bottom line: The latest evidence is very mixed. Some of these care models can save modest amounts of money and keep people healthy, but spending is higher for the millions of people who have been "ping-ponging" in and out of ACOs.
Photo: Aytug Can Sencar/Anadolu Agency/Getty Images
Medicare is considering paying for acupuncture — which would be a controversial move, the Washington Post reports.
Yes, but: There's research showing that in many cases, acupuncture isn't much more effective than a placebo.
Have a great 4th of July. Vitals will be off tomorrow and Friday, but will be back in your inbox on Monday.